MISSION VIEJO, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today that after review of the Company’s white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval. The invitation to submit a proposal by BARDA and Aeolus’ proposal are non-binding, and the selection of the Company’s white paper for submission of a full proposal is not a guarantee of a contract, which will be subject to a favorable technical and scientific review and negotiation of fair and reasonable contract terms.
